CYP2C19: Clopidogrel, SSRIs, and Proton Pump Inhibitors
What Is CYP2C19?
CYP2C19 is a gene that encodes a cytochrome P450 enzyme responsible for metabolizing a significant number of commonly prescribed medications. This enzyme, produced primarily in the liver, plays a central role in the body's ability to activate or break down drugs so they can exert their therapeutic effects and be eliminated from the body.
CYP2C19 is part of the larger cytochrome P450 superfamily — a group of enzymes that collectively metabolize an estimated 70–80% of all clinically used drugs. CYP2C19 specifically handles antiplatelet agents, proton pump inhibitors (PPIs), certain antidepressants (SSRIs and tricyclics), antifungals, and antiepileptic medications. Understanding your CYP2C19 status is a foundational part of pharmacogenomics and is covered in our guide to DNA testing for medication. See also how pharmacogenomic testing works for a step-by-step walkthrough from raw data to report.
Metabolizer Types (Phenotypes)
Based on the combination of CYP2C19 alleles you carry (your diplotype), you are classified into one of several metabolizer phenotypes. These categories predict your enzyme activity level and are used in clinical guidelines to inform prescribing decisions. For a plain-language explanation, see what metabolizer status means.
| Phenotype | Typical Diplotype | Enzyme Activity | What It Means | Example Drug Impact |
|---|---|---|---|---|
| Ultrarapid (UM) | *1/*17 or *17/*17 | Enhanced | Increased gene transcription produces more enzyme. Drugs cleared faster. | Clopidogrel may be more effective; SSRIs may be cleared too fast |
| Normal (NM) | *1/*1 | Standard | Two normal-function alleles. Standard dosing applies. | Drug labels and standard doses are designed for this group |
| Intermediate (IM) | *1/*2 or *1/*3 | Reduced | One no-function allele. Moderately reduced drug clearance. | Clopidogrel activation reduced; consider alternative antiplatelet |
| Poor (PM) | *2/*2, *2/*3, *3/*3 | Absent/minimal | Two no-function alleles. Significantly reduced or no enzyme activity. | Clopidogrel likely ineffective; SSRIs accumulate; PPIs over-suppression |
Approximately 2–15% of the population are CYP2C19 poor metabolizers, with significant variation across ancestry groups. Poor metabolizer frequency is higher in East Asian populations (~12–23%) compared to European (~2–5%) and African (~1–7.5%) populations. Ultrarapid metabolizers are more common in European (~21% carry at least one *17) and African populations.
CYP2C19 and Clopidogrel: Why It Matters
Clopidogrel (Plavix) is one of the most prescribed antiplatelet drugs worldwide, used to prevent blood clots after heart attacks, strokes, and stent placement. It is a prodrug — meaning it is inactive as swallowed and requires CYP2C19 to convert it into its active metabolite.
CYP2C19 poor and intermediate metabolizers may not adequately activate clopidogrel. This has measurable clinical consequences: studies have shown that CYP2C19 loss-of-function carriers have a higher rate of major adverse cardiovascular events (MACE), including stent thrombosis, when treated with clopidogrel compared to normal metabolizers.
The FDA has placed a boxed warning on clopidogrel specifically mentioning CYP2C19 poor metabolizers, recommending that prescribers consider alternative antiplatelet agents such as prasugrel or ticagrelor for these patients. Several cardiology guidelines now support considering CYP2C19 testing to guide antiplatelet selection, particularly after percutaneous coronary intervention (PCI) with stent placement.
CYP2C19 testing is also relevant in stroke care. For patients with minor ischemic stroke or transient ischemic attack (TIA), some guidelines recommend genotype-guided antiplatelet selection to reduce recurrence risk. This is an area of active research and evolving clinical practice — discuss with your cardiologist or neurologist.
Drug Interactions by CYP2C19 Phenotype
The following table summarizes CPIC-guided clinical implications for selected CYP2C19-dependent medications. Consult your healthcare provider for guidance specific to your medications.
| Drug | Class | Effect in Poor Metabolizers | Effect in Ultrarapid Metabolizers | Guideline |
|---|---|---|---|---|
| Clopidogrel | Antiplatelet | Reduced activation — higher cardiovascular event risk; consider prasugrel or ticagrelor | Enhanced activation — may increase bleeding risk at standard doses | CPIC Level A + FDA boxed warning |
| Escitalopram | SSRI | Higher drug levels — consider 50% dose reduction | Lower levels — consider alternative SSRI or dose increase | CPIC Level A |
| Sertraline | SSRI | Higher drug levels — consider alternative or reduce dose | Lower levels — consider dose increase or alternative | CPIC Level A |
| Amitriptyline | TCA | Higher levels — consider dose reduction | Lower levels — consider dose increase or alternative | CPIC Level A |
| Omeprazole | PPI | Slower clearance — higher acid suppression; dose reduction possible | Faster clearance — may need increased dose for H. pylori eradication | CPIC Level A |
| Lansoprazole | PPI | Higher drug exposure — greater acid suppression | Reduced effectiveness — consider dose increase | CPIC Level A |
| Voriconazole | Antifungal | Much higher levels — increase toxicity risk; reduce dose | Lower levels — consider dose increase or therapeutic monitoring | CPIC Level A |
| Clobazam | Antiepileptic | Higher active metabolite levels — reduce dose by 50% | Standard dosing typically applies | CPIC Level A |
Source: CPIC Gene-Drug Pairs and FDA Table of Pharmacogenomic Biomarkers. For a comparison of testing services that report CYP2C19, see our GeneSight cost and alternatives guide.
Common CYP2C19 Variants
Several key genetic variants define CYP2C19 function:
- CYP2C19*1: The reference (wild-type) allele with normal enzyme function.
- CYP2C19*2 (rs4244285): The most common no-function allele worldwide. A splice site variant in exon 5 creates a premature stop codon, producing a nonfunctional protein. Frequency: ~15% in Europeans, ~30% in East Asians.
- CYP2C19*3 (rs4986893): Another no-function allele caused by a premature stop codon in exon 4. Rare in Europeans, more common in East Asians (~2–9%).
- CYP2C19*17 (rs12248560): An increased-function allele caused by a promoter variant that increases gene transcription. Common in Europeans (~21%) and Africans (~16%), less common in East Asians (~3%).
How CYP2C19 Is Tested
CYP2C19 testing is available through several approaches:
- Clinical pharmacogenomic panels: Tests like GeneSight and Genomind include CYP2C19 as a core gene. These require a clinician order and are classified as diagnostic tests. See our comparison of pharmacogenomic testing options.
- Consumer raw data analysis: 23andMe and AncestryDNA arrays cover the variants defining *2, *17, and sometimes *3 — which is sufficient to identify the most common metabolizer phenotypes. Services like DecodeMyBio can analyze your existing DNA data against CPIC guidelines. Unlike CYP2D6, CYP2C19 does not have common structural variants (gene deletions or duplications), so consumer array results are generally reliable.
- Point-of-care testing: Some cardiology centers now offer rapid CYP2C19 genotyping at the time of stent placement (PCI) to guide immediate antiplatelet selection. This is an emerging practice that reflects the growing clinical importance of CYP2C19 testing in cardiovascular care.
For details on how raw data is mapped to star alleles and phenotypes, see our methodology page.
Limitations
CYP2C19 testing — whether clinical or consumer-grade — has important limitations:
- Not diagnostic: CYP2C19 results do not diagnose any cardiovascular, psychiatric, or gastrointestinal condition. They provide pharmacogenomic context for medication discussions with a clinician.
- One factor among many: Drug response is influenced by age, weight, kidney and liver function, other medications, diet, and additional genetic factors. CYP2C19 status alone does not determine drug outcomes.
- Requires clinician interpretation: CYP2C19 results should be interpreted by a healthcare provider in clinical context. Do not change medications — especially antiplatelet therapy after a cardiac event — based solely on genetic results.
- Drug interactions matter: Some drugs inhibit CYP2C19 activity (e.g., omeprazole can reduce clopidogrel activation), and these drug–drug interactions can alter effective phenotype independently of genotype.
- Rare alleles may be missed: Consumer arrays reliably detect *2, *3, and *17, but rarer loss-of-function alleles may not be captured. Clinical panels may test a broader allele panel.
For a comprehensive discussion, see our full limitations page.
CYP2C19 and Psychiatric Medications
CYP2C19 is the primary metabolic pathway for several widely prescribed SSRIs including escitalopram and sertraline. Poor metabolizers may experience higher side effect burden, while ultrarapid metabolizers may have sub-therapeutic levels at standard doses. See our guide to CYP2C19 and SSRI metabolism for details. DecodeMyBio's Psychiatric Medication Report maps your CYP2C19 and CYP2D6 results to CPIC guidelines.
Psychiatric Medication Report · PGx for depression · PGx for anxiety
Frequently Asked Questions
Does CYP2C19 affect antidepressants?
Yes. CYP2C19 is the primary metabolic pathway for escitalopram, citalopram, and sertraline. Poor metabolizers may experience higher drug levels and more side effects. Ultrarapid metabolizers may not reach therapeutic levels at standard doses. CPIC guidelines recommend dose adjustments or alternative medications based on phenotype. See our CYP2C19 and SSRI guide.
What happens if clopidogrel doesn't work because of CYP2C19?
CYP2C19 poor and intermediate metabolizers may not adequately activate clopidogrel, leaving them at higher risk for cardiovascular events. The FDA boxed warning recommends considering alternative antiplatelet therapy (prasugrel or ticagrelor) for poor metabolizers. Discuss with your cardiologist.
How does CYP2C19 affect proton pump inhibitors?
CYP2C19 is the primary enzyme that breaks down PPIs like omeprazole and lansoprazole. Poor metabolizers clear PPIs more slowly, leading to higher drug levels. Ultrarapid metabolizers clear PPIs faster, which may reduce effectiveness for H. pylori eradication.
Is CYP2C19 testing recommended before starting clopidogrel?
Several professional guidelines support considering CYP2C19 testing when starting clopidogrel, particularly after stent placement. The FDA boxed warning mentions poor metabolizers. Testing is not yet universally required but is increasingly adopted in cardiovascular practice.
Does CYP2C19 status affect stroke treatment?
CYP2C19 status is relevant when clopidogrel is prescribed for secondary stroke prevention. Some stroke guidelines recommend genotype-guided antiplatelet selection for patients with minor ischemic stroke or TIA. This is an evolving area of clinical practice.
What is the difference between CYP2C19 and CYP2D6?
Both are drug-metabolizing enzymes, but they affect different medications. CYP2D6 primarily affects opioids, TCAs, some SSRIs (paroxetine), antipsychotics, and tamoxifen. CYP2C19 primarily affects clopidogrel, PPIs, and some SSRIs (escitalopram, sertraline). CYP2C19 does not have the structural variant complexity that makes CYP2D6 challenging for consumer genotyping.
Can 23andMe determine my CYP2C19 status?
23andMe's genotyping array covers the variants defining CYP2C19 *2 and *17. A dedicated raw data analysis can extract these variants and map the result to CPIC guidelines. See our guide to pharmacogenomic insights from raw DNA.
Does CYP2C19 testing replace clinical judgment?
No. CYP2C19 results are one input among many. Drug response depends on age, weight, organ function, other medications, and additional factors. Results should always be interpreted by a healthcare provider — especially for antiplatelet therapy decisions after cardiac events.
Get Your CYP2C19 Results
If you have raw DNA data from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA, you can upload it to DecodeMyBio to learn your CYP2C19 metabolizer status. Your Medication Safety Report will include your CYP2C19 diplotype, metabolizer phenotype, and CPIC-guideline drug-gene interactions relevant to your genotype.
Upload your data · View a sample report · What to do with your 23andMe raw data
Related Genes and Reports
CYP2C19 is one of several pharmacogenes analyzed in your report. Related genes include CYP2D6 (antidepressants, opioids), CYP2C9 and VKORC1 (warfarin dosing), and MTHFR (folate metabolism). For a nutrigenomic analysis from the same DNA data, see our Nutrition & Methylation Report. Browse our learning center for more guides.
Last reviewed: March 2026 · DecodeMyBio Editorial Team